NCT03441061View on ClinicalTrials.gov

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Inotuzumab Ozogamicin

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER